Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study

Acta Oncologica

Volumn 53, Issue 7, 2014, Pages 939-944

  Hofland, Kenneth F ^a   Hansen, Steinbjørn ^b   Sorensen, Morten ^a   Engelholm, Silke ^a   Schultz, Henrik P ^c   Muhic, Aida ^a   Grunnet, Kirsten ^a   Ask, Anders ^a   Costa, Junia C ^a   Kristiansen, Charlotte ^b   Thomsen, Carsten ^a   Poulsen, Hans Skovgaard ^a   Lassen, Ulrik ^a  

^a University of Copenhagen   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DACARBAZINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; VOMITING; ADJUVANT THERAPY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PROCEDURES; TREATMENT OUTCOME; DEATH; GRANULOCYTOPENIA; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; RADIATION DOSE FRACTIONATION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; TREATMENT OUTCOME;

EID: 84903279656     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.879607     Document Type: Article

References (25)

1. Ferrara N, Gerber H P, LeCouter J . The biology of VEGF and its receptors . Nat Med 2003; 9: 669-76.
2. Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, et al. A review of VEGF/ VEGFR-targeted therapeutics for recurrent glioblastoma . J Natl Compr Canc Netw 2011; 9: 414-27.
3. Gerber HP, Ferrara N . Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies . Cancer Res 2005; 65: 671-80.
4. Moller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, et al. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy . Acta Oncol 2012; 51: 797-804.
5. Stark-Vance V . Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma . Neuro-Oncol 2005; 7: 369.
6. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme . J Clin Oncol 2007; 25: 4722-9.
7. Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours . Acta Oncol 2009; 48: 52-8.
8. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sorensen M, Kosteljanetz M, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial . Neuro Oncol 2010; 12: 508-16.
9. Friedman H S, Prados M D, Wen P Y, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma . J Clin Oncol 2009; 27: 4733-40.
10. Kreisl T N, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma . J Clin Oncol 2009; 27: 740-5.
11. Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE, et al. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme . Int J Radiat Oncol Biol Phys 2012; 82: 58-66.
12. Lai A, Tran A, Nghiemphu P L, Pope W B, Solis OE, Selch M, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme . J Clin Oncol 2011; 29: 142-8 . Emami B
13. Lyman J, Brown A, Coia L, G oitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation . Int J Radiat Oncol Biol Phys 1991; 21: 109-22.
14. Gilbert M R, Friedman H S, Kuttesch J F, Prados M D, Olson J J, Reaman GH, et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy . Neuro Oncol 2002; 4: 261-7.
15. Friedman H S, McLendon R E, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma . J Clin Oncol 1998; 16: 3851-7.
16. Brada M, Ashley S, Dowe A, Gonsalves A, Huchet A, Pesce G, et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide . Ann Oncol 2005; 16: 942-9.
17. Hygino da Cruz LC, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG . Pseudoprogression and pseudoresponse: Imaging challenges in the assessment of posttreatment glioma . Am J Neuroradiology 2011; 32: 1978-85.
18. Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newlydiagnosed glioblasoma: Mature progression-free survival and preliminary overall survival results in Avaglio . Neuro- Oncology 2012; 14(Suppl 6): 101-5.
19. Gilbert M R, Dignam J, Won M, Blumenthal D T, Vogelbaum MA, Aldape KD, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM) [abstract] . J Clin Oncol ASCO Annual Meeting Proceedings 2013; 31: 1.
20. Olson RA, Brastianos PK, Palma DA . Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: A systematic review and meta-analysis . J Neurooncol 2011; 105: 325-35.
21. Herrlinger U, Schaefer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, et al. Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial [abstract] . J Clin Oncol ASCO Annual Meeting Proceedings 2013; 31: LBA2000.
22. Stupp R, Mason W P, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma . N Engl J Med 2005; 352: 987-96.
23. Gilbert M .R, Wang M, Aldape K D, Stupp R, Hegi M, Jaeckle KA, et al. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM) [abstract] . J Clin Oncol ASCO Annual Meeting Proceedings 2011: 29: 2006.
24. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE, Marcello J, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma . Clin Cancer Res 2011; 15; 4119-24.
25. Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma . J Neurosurg 2012; 116: 341-5.